Concepts (219)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 67 | 2024 | 643 | 13.570 |
Why?
|
| Hypoglycemic Agents | 43 | 2024 | 160 | 8.930 |
Why?
|
| Insulin | 23 | 2024 | 236 | 8.090 |
Why?
|
| Diabetes Mellitus | 37 | 2022 | 485 | 7.340 |
Why?
|
| Prediabetic State | 10 | 2023 | 53 | 5.680 |
Why?
|
| Blood Glucose | 34 | 2024 | 353 | 4.930 |
Why?
|
| Thiazolidinediones | 10 | 2020 | 50 | 3.540 |
Why?
|
| Blood Glucose Self-Monitoring | 10 | 2024 | 29 | 3.420 |
Why?
|
| Diabetes Mellitus, Type 1 | 9 | 2024 | 68 | 2.650 |
Why?
|
| Cardiovascular Diseases | 8 | 2023 | 664 | 2.500 |
Why?
|
| Primary Health Care | 5 | 2024 | 294 | 2.200 |
Why?
|
| Metformin | 6 | 2020 | 65 | 2.140 |
Why?
|
| Humans | 115 | 2024 | 37093 | 2.030 |
Why?
|
| Algorithms | 11 | 2024 | 465 | 1.820 |
Why?
|
| Life Style | 6 | 2023 | 308 | 1.650 |
Why?
|
| Glucose Tolerance Test | 10 | 2012 | 68 | 1.650 |
Why?
|
| Glucose Intolerance | 5 | 2023 | 42 | 1.470 |
Why?
|
| Insulin Resistance | 5 | 2013 | 184 | 1.330 |
Why?
|
| Hyperglycemia | 6 | 2022 | 55 | 1.300 |
Why?
|
| Patient Education as Topic | 7 | 2017 | 215 | 1.270 |
Why?
|
| Diabetic Retinopathy | 3 | 2016 | 68 | 1.260 |
Why?
|
| Societies, Medical | 10 | 2014 | 66 | 1.170 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2017 | 63 | 1.100 |
Why?
|
| Research Support as Topic | 5 | 2004 | 80 | 1.080 |
Why?
|
| Middle Aged | 29 | 2024 | 10129 | 0.990 |
Why?
|
| Male | 36 | 2024 | 20025 | 0.930 |
Why?
|
| Quality of Life | 5 | 2014 | 481 | 0.930 |
Why?
|
| Fasting | 9 | 2020 | 54 | 0.920 |
Why?
|
| Diabetes Complications | 3 | 2009 | 90 | 0.900 |
Why?
|
| Adult | 22 | 2023 | 11712 | 0.900 |
Why?
|
| Vitamin D | 3 | 2021 | 196 | 0.890 |
Why?
|
| Insulin Infusion Systems | 2 | 2024 | 4 | 0.830 |
Why?
|
| Female | 34 | 2024 | 20969 | 0.830 |
Why?
|
| Sulfonylurea Compounds | 2 | 2019 | 12 | 0.770 |
Why?
|
| Minority Groups | 4 | 2007 | 596 | 0.720 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2019 | 4 | 0.720 |
Why?
|
| Hydroxychloroquine | 1 | 2019 | 15 | 0.700 |
Why?
|
| Urinary Tract Infections | 1 | 2019 | 35 | 0.690 |
Why?
|
| Risk Factors | 11 | 2023 | 3562 | 0.670 |
Why?
|
| Aged | 16 | 2019 | 6741 | 0.670 |
Why?
|
| Self Care | 6 | 2017 | 159 | 0.650 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2014 | 268 | 0.630 |
Why?
|
| Albuminuria | 2 | 2011 | 76 | 0.620 |
Why?
|
| Clinical Protocols | 1 | 2017 | 36 | 0.610 |
Why?
|
| United States | 20 | 2014 | 4223 | 0.580 |
Why?
|
| Cholesterol, LDL | 5 | 2017 | 68 | 0.580 |
Why?
|
| Cost-Benefit Analysis | 6 | 2020 | 144 | 0.560 |
Why?
|
| Obesity | 4 | 2022 | 1067 | 0.550 |
Why?
|
| Weight Loss | 3 | 2023 | 131 | 0.530 |
Why?
|
| Reproducibility of Results | 11 | 2010 | 935 | 0.520 |
Why?
|
| Drug Therapy, Combination | 7 | 2019 | 227 | 0.520 |
Why?
|
| Reminder Systems | 2 | 2005 | 13 | 0.500 |
Why?
|
| Health Transition | 1 | 2014 | 4 | 0.480 |
Why?
|
| Sertraline | 2 | 2011 | 7 | 0.480 |
Why?
|
| Disease Management | 3 | 2014 | 61 | 0.470 |
Why?
|
| Dyslipidemias | 1 | 2014 | 43 | 0.470 |
Why?
|
| Outsourced Services | 2 | 2004 | 5 | 0.470 |
Why?
|
| Antidepressive Agents | 2 | 2011 | 50 | 0.460 |
Why?
|
| Double-Blind Method | 4 | 2023 | 286 | 0.460 |
Why?
|
| Diabetes, Gestational | 2 | 2020 | 47 | 0.460 |
Why?
|
| Delivery of Health Care | 3 | 2009 | 276 | 0.450 |
Why?
|
| Glucose Clamp Technique | 1 | 2013 | 7 | 0.440 |
Why?
|
| Nursing Care | 2 | 2010 | 7 | 0.440 |
Why?
|
| Blood Pressure | 6 | 2017 | 646 | 0.420 |
Why?
|
| Research Design | 1 | 2014 | 313 | 0.420 |
Why?
|
| Pyrazines | 1 | 2011 | 24 | 0.400 |
Why?
|
| Pharmacists | 2 | 2009 | 53 | 0.390 |
Why?
|
| Triazoles | 1 | 2011 | 86 | 0.380 |
Why?
|
| Postprandial Period | 1 | 2010 | 10 | 0.370 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2010 | 26 | 0.370 |
Why?
|
| Hypertension | 2 | 2014 | 796 | 0.360 |
Why?
|
| Treatment Outcome | 7 | 2011 | 1369 | 0.360 |
Why?
|
| Injections | 3 | 2019 | 35 | 0.350 |
Why?
|
| Prevalence | 5 | 2017 | 1455 | 0.350 |
Why?
|
| Breath Tests | 1 | 2009 | 24 | 0.350 |
Why?
|
| Carbon Isotopes | 1 | 2009 | 38 | 0.350 |
Why?
|
| Depressive Disorder | 1 | 2011 | 174 | 0.340 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 974 | 0.340 |
Why?
|
| Drug Administration Schedule | 4 | 2014 | 143 | 0.330 |
Why?
|
| Cohort Studies | 3 | 2019 | 1492 | 0.330 |
Why?
|
| Hospitalization | 3 | 2008 | 388 | 0.330 |
Why?
|
| Needles | 1 | 2008 | 9 | 0.330 |
Why?
|
| Cholecalciferol | 2 | 2021 | 20 | 0.320 |
Why?
|
| Thyrotropin | 1 | 2008 | 17 | 0.310 |
Why?
|
| Diabetic Angiopathies | 3 | 2020 | 21 | 0.300 |
Why?
|
| Glyburide | 1 | 2007 | 8 | 0.300 |
Why?
|
| Managed Care Programs | 1 | 2007 | 38 | 0.280 |
Why?
|
| Insulin, Long-Acting | 2 | 2020 | 3 | 0.280 |
Why?
|
| Islam | 1 | 2006 | 16 | 0.270 |
Why?
|
| Treatment Failure | 2 | 2019 | 64 | 0.270 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2014 | 1039 | 0.260 |
Why?
|
| Drug Costs | 2 | 2020 | 28 | 0.260 |
Why?
|
| Venoms | 1 | 2005 | 15 | 0.260 |
Why?
|
| Hemoglobins, Abnormal | 1 | 2005 | 5 | 0.260 |
Why?
|
| Medicine, Ayurvedic | 1 | 2004 | 9 | 0.250 |
Why?
|
| Reagent Strips | 1 | 2004 | 2 | 0.240 |
Why?
|
| Community Health Centers | 2 | 2005 | 45 | 0.240 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2004 | 11 | 0.240 |
Why?
|
| Costs and Cost Analysis | 2 | 2020 | 57 | 0.240 |
Why?
|
| Body Mass Index | 2 | 2023 | 854 | 0.240 |
Why?
|
| Arteriosclerosis | 1 | 2004 | 36 | 0.230 |
Why?
|
| Phytotherapy | 1 | 2004 | 81 | 0.230 |
Why?
|
| Peer Review, Research | 1 | 2003 | 10 | 0.230 |
Why?
|
| Medication Adherence | 2 | 2017 | 179 | 0.230 |
Why?
|
| Specialties, Nursing | 1 | 2003 | 1 | 0.230 |
Why?
|
| Inpatients | 1 | 2004 | 74 | 0.230 |
Why?
|
| Enalapril | 1 | 2002 | 7 | 0.220 |
Why?
|
| Gastric Inhibitory Polypeptide | 1 | 2022 | 2 | 0.220 |
Why?
|
| Depression | 1 | 2009 | 712 | 0.220 |
Why?
|
| Peptides | 1 | 2005 | 320 | 0.210 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2002 | 69 | 0.210 |
Why?
|
| Vitamins | 2 | 2021 | 94 | 0.210 |
Why?
|
| Glucose | 2 | 2017 | 230 | 0.200 |
Why?
|
| Canada | 1 | 2022 | 130 | 0.200 |
Why?
|
| Young Adult | 4 | 2014 | 4268 | 0.200 |
Why?
|
| Periodicals as Topic | 1 | 2002 | 49 | 0.200 |
Why?
|
| Risk | 2 | 2017 | 267 | 0.190 |
Why?
|
| Europe | 4 | 2014 | 101 | 0.180 |
Why?
|
| Pregnancy | 2 | 2020 | 1549 | 0.180 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2019 | 10 | 0.180 |
Why?
|
| Practice Guidelines as Topic | 3 | 2007 | 191 | 0.180 |
Why?
|
| Time Factors | 2 | 2019 | 1742 | 0.180 |
Why?
|
| Nutrition Surveys | 2 | 2014 | 242 | 0.170 |
Why?
|
| Antimalarials | 1 | 2019 | 55 | 0.170 |
Why?
|
| Family Characteristics | 1 | 2020 | 108 | 0.170 |
Why?
|
| Sex Factors | 2 | 2014 | 898 | 0.160 |
Why?
|
| Community Health Services | 2 | 2014 | 185 | 0.160 |
Why?
|
| Disease Progression | 1 | 2020 | 601 | 0.150 |
Why?
|
| Aged, 80 and over | 2 | 2014 | 2379 | 0.150 |
Why?
|
| Injections, Subcutaneous | 1 | 2017 | 33 | 0.150 |
Why?
|
| Pilot Projects | 1 | 2019 | 661 | 0.140 |
Why?
|
| Mass Screening | 2 | 2014 | 462 | 0.140 |
Why?
|
| Prognosis | 1 | 2019 | 739 | 0.140 |
Why?
|
| Drug Industry | 1 | 2016 | 14 | 0.140 |
Why?
|
| History, 20th Century | 1 | 2016 | 117 | 0.130 |
Why?
|
| Los Angeles | 4 | 2005 | 380 | 0.130 |
Why?
|
| Prospective Studies | 1 | 2019 | 1378 | 0.130 |
Why?
|
| Quality Assurance, Health Care | 2 | 2007 | 56 | 0.130 |
Why?
|
| California | 2 | 2007 | 476 | 0.120 |
Why?
|
| Dietary Supplements | 2 | 2014 | 208 | 0.120 |
Why?
|
| Medical History Taking | 1 | 2014 | 33 | 0.120 |
Why?
|
| Overweight | 1 | 2016 | 247 | 0.120 |
Why?
|
| Tissue Distribution | 1 | 2014 | 207 | 0.120 |
Why?
|
| Waist Circumference | 1 | 2014 | 89 | 0.110 |
Why?
|
| Patient Satisfaction | 1 | 2014 | 145 | 0.110 |
Why?
|
| Lipids | 1 | 2014 | 235 | 0.110 |
Why?
|
| Behavior Therapy | 1 | 2014 | 167 | 0.110 |
Why?
|
| Health Status | 1 | 2014 | 380 | 0.100 |
Why?
|
| Retrospective Studies | 2 | 2007 | 2026 | 0.090 |
Why?
|
| Adolescent | 2 | 2011 | 5363 | 0.090 |
Why?
|
| Socioeconomic Factors | 1 | 2014 | 1067 | 0.090 |
Why?
|
| C-Peptide | 1 | 2009 | 7 | 0.090 |
Why?
|
| Placebos | 1 | 2009 | 37 | 0.090 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2009 | 19 | 0.080 |
Why?
|
| Insulin-Secreting Cells | 1 | 2009 | 28 | 0.080 |
Why?
|
| Carbon Dioxide | 1 | 2009 | 77 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2008 | 562 | 0.080 |
Why?
|
| Cholesterol, HDL | 1 | 2009 | 97 | 0.080 |
Why?
|
| Regression Analysis | 1 | 2010 | 455 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 400 | 0.080 |
Why?
|
| Population Surveillance | 1 | 2010 | 238 | 0.080 |
Why?
|
| Diabetic Nephropathies | 1 | 2009 | 61 | 0.080 |
Why?
|
| Health Surveys | 1 | 2010 | 373 | 0.080 |
Why?
|
| Administration, Oral | 1 | 2008 | 224 | 0.080 |
Why?
|
| Chronic Disease | 1 | 2011 | 484 | 0.080 |
Why?
|
| Homeostasis | 2 | 2014 | 188 | 0.080 |
Why?
|
| Nurses | 1 | 2007 | 48 | 0.070 |
Why?
|
| Body Weight | 1 | 2009 | 434 | 0.070 |
Why?
|
| ROC Curve | 1 | 2007 | 138 | 0.070 |
Why?
|
| Age Factors | 1 | 2010 | 1033 | 0.070 |
Why?
|
| Patient Care Planning | 1 | 2006 | 14 | 0.070 |
Why?
|
| Focus Groups | 2 | 2005 | 348 | 0.070 |
Why?
|
| Lung | 1 | 2009 | 446 | 0.070 |
Why?
|
| Dietary Carbohydrates | 1 | 2006 | 31 | 0.070 |
Why?
|
| Angina, Unstable | 1 | 2005 | 8 | 0.070 |
Why?
|
| United States Food and Drug Administration | 1 | 2005 | 22 | 0.070 |
Why?
|
| Drug Approval | 1 | 2005 | 8 | 0.070 |
Why?
|
| Weight Gain | 1 | 2006 | 136 | 0.070 |
Why?
|
| Arizona | 1 | 2005 | 100 | 0.070 |
Why?
|
| Marketing | 1 | 2005 | 40 | 0.060 |
Why?
|
| Triglycerides | 1 | 2005 | 138 | 0.060 |
Why?
|
| Continuity of Patient Care | 1 | 2005 | 94 | 0.060 |
Why?
|
| Age of Onset | 1 | 2004 | 100 | 0.060 |
Why?
|
| Sexual Behavior | 1 | 2009 | 609 | 0.060 |
Why?
|
| Patient Compliance | 1 | 2005 | 212 | 0.060 |
Why?
|
| Single-Blind Method | 1 | 2003 | 55 | 0.060 |
Why?
|
| Electrocardiography | 1 | 2004 | 156 | 0.060 |
Why?
|
| Medicare | 1 | 2005 | 195 | 0.060 |
Why?
|
| Reference Values | 1 | 2003 | 212 | 0.060 |
Why?
|
| Length of Stay | 1 | 2004 | 185 | 0.060 |
Why?
|
| Guideline Adherence | 1 | 2003 | 84 | 0.060 |
Why?
|
| Myocardial Infarction | 1 | 2005 | 225 | 0.060 |
Why?
|
| Interprofessional Relations | 1 | 2003 | 54 | 0.050 |
Why?
|
| Proteinuria | 1 | 2002 | 50 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 1 | 2003 | 111 | 0.050 |
Why?
|
| Heart Failure | 1 | 2005 | 235 | 0.050 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2003 | 77 | 0.050 |
Why?
|
| Anxiety | 1 | 2009 | 754 | 0.050 |
Why?
|
| Coronary Disease | 1 | 2003 | 124 | 0.050 |
Why?
|
| Educational Status | 1 | 2003 | 313 | 0.050 |
Why?
|
| Communication | 1 | 2003 | 180 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2002 | 217 | 0.050 |
Why?
|
| Apoptosis | 1 | 2009 | 1398 | 0.050 |
Why?
|
| Patient Selection | 1 | 2002 | 164 | 0.050 |
Why?
|
| Urban Population | 1 | 2003 | 333 | 0.050 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2012 | 4 | 0.030 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2008 | 5 | 0.020 |
Why?
|
| Competency-Based Education | 1 | 2005 | 10 | 0.020 |
Why?
|
| Child | 1 | 2012 | 3131 | 0.010 |
Why?
|
| Pravastatin | 1 | 2003 | 6 | 0.010 |
Why?
|
| Lovastatin | 1 | 2003 | 10 | 0.010 |
Why?
|
| Heptanoic Acids | 1 | 2003 | 12 | 0.010 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2003 | 20 | 0.010 |
Why?
|
| Simvastatin | 1 | 2003 | 29 | 0.010 |
Why?
|
| Pyrroles | 1 | 2003 | 55 | 0.010 |
Why?
|
| Community-Institutional Relations | 1 | 2005 | 187 | 0.010 |
Why?
|
| Health Personnel | 1 | 2005 | 228 | 0.010 |
Why?
|
| Indoles | 1 | 2003 | 158 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2005 | 864 | 0.010 |
Why?
|